iHuman Institute, ShanghaiTech University, School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
iHuman Institute, ShanghaiTech University, Shanghai 201210, China.
Molecules. 2023 Jan 11;28(2):751. doi: 10.3390/molecules28020751.
Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and blood glucose regulation has been extensively studied. Numerous drugs targeting GLP-1R have entered clinical treatment. However, novel functional molecules with reduced side effects and enhanced therapeutic efficacy are still in high demand. In this review, we summarize the basis of GLP-1R cellular signaling, and how it is involved in the treatment of T2DM. We review the functional molecules of incretin therapy in various stages of clinical trials. We also outline the current strategies and emerging techniques that are furthering the development of novel therapeutic drugs for T2DM and other metabolic diseases.
胰高血糖素样肽-1 受体（GLP-1R）是 2 型糖尿病（T2DM）的重要治疗靶点。与胰岛素分泌和血糖调节相关的 GLP-1R 细胞信号转导机制已得到广泛研究。许多针对 GLP-1R 的药物已进入临床治疗。然而，仍需要具有减少副作用和增强治疗效果的新型功能分子。在这篇综述中，我们总结了 GLP-1R 细胞信号转导的基础，以及它如何参与 T2DM 的治疗。我们回顾了在临床试验各个阶段的肠促胰岛素治疗的功能分子。我们还概述了目前正在推进用于治疗 T2DM 和其他代谢性疾病的新型治疗药物开发的策略和新兴技术。
